Inhaled loxapine for rapid treatment of agitation in schizophrenia and bipolar disorder: An update

Neuropsychiatry

Volumn 2, Issue 3, 2012, Pages 253-260

  Nordstrom, Kimberly ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; CENTRAL DEPRESSANT AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LOXAPINE; SEROTONIN ANTAGONIST; STACCATO; UNCLASSIFIED DRUG;

AGITATION; BIPOLAR DISORDER; BRONCHOSPASM; DIARRHEA; DIZZINESS; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPESTHESIA; NAUSEA; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMACH DISCOMFORT; TASTE DISORDER; THROAT IRRITATION; VOMITING; WHEEZING;

EID: 84876509596     PISSN: 17582008     EISSN: 17582016     Source Type: Journal    
DOI: 10.2217/npy.12.23     Document Type: Review

References (34)

1. Mittal V, Muralee S, Williamson D et al. Review: delirium in the elderly: a comprehensive review. Am. J. Alz. Dis. Other Demen. 26, 97-109 (2011).
2. Ciurli P, Formisano R, Bivona U et al. Neuropsychiatric disorders in persons with severe traumatic brain injury: prevalence, phenomenology, and relationship with demographic, clinical, and functional features. J. Head Trauma Rehabil. 26, 116-126 (2011).
3. Caplan LR. Delirium: a neurologist's view - the neurology of agitation and overactivity. Rev. Neurol. Dis. 7, 111-118 (2010).
4. Saitz R. Introduction to alcohol withdrawal. Alcohol Health Res. World 22, 5-12 (1998).
5. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv. Rev. Psychiatry 9(3), 89-104 (2001).
6. Alderfer B, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J. Clin. Psychiatry 64(Suppl. 4), 3-9 (2003).
7. Nordstrom K, Zun LS, Wilson MP et al. Medical evaluation and triage of the agitated patient: consensus statement of the American Association for emergency psychiatry project BETA medical evaluation workgroup. West J. Emerg. Med. 13(1), 3-10 (2012).
8. Lindenmayer JP. The pathophysiology of agitation. J. Clin. Psychiatry 60(Suppl. 14), 5-10 (2000).
9. Damsa C, Ikelheimer D, Adam E et al. Heisenberg in the ER: observation appears to reduce involuntary intramuscular injections in a psychiatric emergency service. Gen. Hosp. Psychiatry 28(5), 431-433 (2006).
10. Swanson JW, Swartz MS et al. A national study of violent behavior. Arch. Gen. Psychiatry 63, 490-499 (2006).
11. Wilson MP, Pepper D, Currier GW, Holloman GH, Feifel D. The psychopharmacology of agitation: consensus statement of the American Association for emergency psychiatry project BETA psychopharmacology workgroup. West J. Emerg. Med. 13 (1), 26-34 (2012). New consensus guidelines in the treatment of agitation.
12. Wright P, Birkett M, David SR et al. Double-blind, placebo controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry 158(7), 1149-1151 (2001).
13. Zimbroff DL, Allen MH, Battaglia J et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr. 10(9), 1-15 (2005).
14. Breier A, Meehan K, Birkett M et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry 59, 441-448 (2002).
15. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 68, 111-119 (2007).
16. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am. J. Emerg. Med. 21, 192-198 (2003).
17. Rabinowitz JD, Wensley M, Lloyd P et al. Fast onset medications through thermally generated aerosols. J. Pharmacol. Exp. Ther. 309(2), 769-775 (2004).
18. Rabinowitz JD, Lloyd PM, Munzar P et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J. Pharm. Sci. 95(11), 2438-2451 (2006).
19. Dinh KV, Myers DJ, Noymer PD, Cassella JV. In vitro aerosol deposition in the oropharyngeal region for Staccato lozapine. J. Aerosol. Med. Pulm. Drug Deliv. 23(4), 253-260 (2010).
20. Simpson GM, Cuculic Z. A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. J. Clin. Pharmacol. 16, 60-65 (1976).
21. Fruensgaard K, Wollenberg J, Hansen KM, Fensbo C, Sihm F. Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. Curr. Med. Res. Opin. 5(8), 601-607 (1978).
22. Goldschmidt TJ, Burch EA. Use of loxapine to treat a patient with psychotic depression. Am. J. Psychiatry 139, 946-947 (1982).
23. Vanelle JM, Olie JP, Levy-Soussan P. New antipsychotics in schizophrenia: the French experience. Acta Psychiatry Scand. Suppl. 380, 59-63 (1994).
24. Chakrabarti A, Bagnall AM, Chue P et al. Loxapine for schizophrenia. Cochrane Database Syst. Rev. Cochrane Lib. 1(4) CD001943 (2007).n Timely review of 41 studies concerning loxapine.
25. Singh AN, Barlas C, Singh S, Franks P, Mishra RK. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J. Psychiatry Neurosci. 21(1), 29-35 (1996).
26. Allen MH, Feifel D, Lesem MD et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 72(10), 1313-1321 (2011). Phase II trial examining the efficacy and safety for inhaled loxapine.
27. Spyker DA, Munzar P, Cassella JV. Pharmakokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J. Clin. Pharmacol. 50(2), 169-179 (2010).
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale for schizophrenia. Schizophrenia Bull. 13, 261-276 (1987).
29. Guy W (Ed.). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville, MD, USA (1976).
30. Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP. Validation of the behavioral activity rating scale (BARS): a novel measure of activity in agitated patients. J. Psychiatry Res. 36(2), 87-95 (2002).
31. Lesem MD, Tran-Johnson TK, Riesenberg RA et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicenter, randomized, placebo-controlled study of inhaled loxapine. Br. J. Psychiatry 198(1), 51-58 (2011). Phase III trial for schizophrenia.
32. Kwentus J, Riesenberg RA, Marandi M et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 14, 31-40 (2012). Phase III trial for bipolar I disorder.
33. News Release: US FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™. www.alexza.com; investor relations-news releases (Accessed 13 December 2011)
34. News Release: Alexza Announces Extension of the ADASUVE™ PDUFA Goal Date by Three Months; New goal Date is May 4, 2012. www.alexza.com; investor relations-news releases (Accessed 23 January 2012)